COVID-19 vaccines: where we stand and challenges ahead

G Forni, A Mantovani - Cell Death & Differentiation, 2021 - nature.com
In the eleven months elapsed since the identification of the SARS-CoV-2 virus and its
genome, an exceptional effort by the scientific community has led to the development of over …

COVID-19 transmission, current treatment, and future therapeutic strategies

VS Salian, JA Wright, PT Vedell, S Nair… - Molecular …, 2021 - ACS Publications
At the stroke of the New Year 2020, COVID-19, a zoonotic disease that would turn into a
global pandemic, was identified in the Chinese city of Wuhan. Although unique in its …

Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study

CH Hansen, D Michlmayr, SM Gubbels, K Mølbak… - The lancet, 2021 - thelancet.com
Background The degree to which infection with SARS-CoV-2 confers protection towards
subsequent reinfection is not well described. In 2020, as part of Denmark's extensive, free-of …

Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic

KKW To, S Sridhar, KHY Chiu, DLL Hung… - Emerging microbes & …, 2021 - Taylor & Francis
Without modern medical management and vaccines, the severity of the Coronavirus
Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome (SARS) …

Efficacy and safety of COVID-19 vaccines in older people

RL Soiza, C Scicluna, EC Thomson - Age and ageing, 2021 - academic.oup.com
Several vaccines against coronavirus disease 2019 (COVID-19) are on the cusp of
regulatory approval. Their safety and efficacy in older people is critical to their success. Even …

SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants

D Martínez-Flores, J Zepeda-Cervantes… - Frontiers in …, 2021 - frontiersin.org
Coronavirus 19 Disease (COVID-19) originating in the province of Wuhan, China in 2019, is
caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), whose …

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind …

P Richmond, L Hatchuel, M Dong, B Ma, B Hu… - The lancet, 2021 - thelancet.com
Background As part of the accelerated development of vaccines against severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), we report a dose-finding and adjuvant …

The potential of selected agri-food loss and waste to contribute to a circular economy: Applications in the food, cosmetic and pharmaceutical industries

LLDR Osorio, E Flórez-López, CD Grande-Tovar - Molecules, 2021 - mdpi.com
The food sector includes several large industries such as canned food, pasta, flour, frozen
products, and beverages. Those industries transform agricultural raw materials into added …

Change of willingness to accept COVID-19 vaccine and reasons of vaccine hesitancy of working people at different waves of local epidemic in Hong Kong, China …

K Wang, ELY Wong, KF Ho, AWL Cheung, PSY Yau… - Vaccines, 2021 - mdpi.com
Vaccine hesitancy is among the major threats to the effectiveness of vaccination
programmes. This study aimed to report the trend in response to willingness to accept the …

[HTML][HTML] A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine

L Chu, R McPhee, W Huang, H Bennett, R Pajon… - Vaccine, 2021 - Elsevier
Background Vaccines are urgently needed to prevent the global spread of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). We assessed the safety and …